Nadine D. van Kleef
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nadine D. van Kleef has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Coen Maas
Central Diagnostic Laboratory Research, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
4 shared publications - Steven de Maat
Central Diagnostic Laboratory Research, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
3 shared publications - Arjan D. Barendrecht
Central Diagnostic Laboratory Research, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
2 shared publications - Chantal C. Clark
University Medical Center Utrecht, Utrecht University, Center for Benign Hematology, Thrombosis and Hemostasis- Van Creveldkliniek, Utrecht, the Netherlands; Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, the Netherlands
2 shared publications - Hinde El Otmani
Central Diagnostic Laboratory Research, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
2 shared publications - Peter J. Lenting
Université Paris-Saclay, Institut National de la Santé et de la Recherche Médicale, Hémostase inflammation thrombose U1176, 94276, Le Kremlin-Bicêtre
2 shared publications
Latest Publications
- Open Access
- 21 December 2022
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 20 (6) , 1412-1420
Altered fibrin network structure and fibrinolysis in intensive care unit patients with COVID‐19, not entirely explaining the increased risk of thrombosis
- 21 December 2022
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 20 (6) , 1412-1420
Open AccessAltered fibrin network structure and fibrinolysis in intensive care unit patients with COVID‐19, not entirely explaining the increased risk of thrombosis
- 18 July 2022
- Published by Springer Nature in Nature Nanotechnology
- Vol. 17 (9) , 1004-1014
Nanomedicine platform for targeting activated neutrophils and neutrophil–platelet complexes using an α1-antitrypsin-derived peptide motif
Targeted drug delivery to disease-associated activated neutrophils can provide novel therapeutic opportunities while avoiding systemic effects on immune functions. We created a nanomedicine platform that uniquely utilizes an α1-antitrypsin-derived peptide to confer binding specificity to neutrophil elastase on activated neutrophils. Surface decoration with this peptide enabled specific anchorage of nanoparticles to activated neutrophils and platelet–neutrophil aggregates, in vitro and in vivo. Nanoparticle delivery of a model drug, hydroxychloroquine, demonstrated significant reduction of neutrophil activities in vitro and a therapeutic effect on murine venous thrombosis in vivo. This innovative approach of cell-specific and activation-state-specific targeting can be applied to several neutrophil-driven pathologies.
- 18 July 2022
- Published by Springer Nature in Nature Nanotechnology
- Vol. 17 (9) , 1004-1014
Nanomedicine platform for targeting activated neutrophils and neutrophil–platelet complexes using an α1-antitrypsin-derived peptide motif
Targeted drug delivery to disease-associated activated neutrophils can provide novel therapeutic opportunities while avoiding systemic effects on immune functions. We created a nanomedicine platform that uniquely utilizes an α1-antitrypsin-derived peptide to confer binding specificity to neutrophil elastase on activated neutrophils. Surface decoration with this peptide enabled specific anchorage of nanoparticles to activated neutrophils and platelet–neutrophil aggregates, in vitro and in vivo. Nanoparticle delivery of a model drug, hydroxychloroquine, demonstrated significant reduction of neutrophil activities in vitro and a therapeutic effect on murine venous thrombosis in vivo. This innovative approach of cell-specific and activation-state-specific targeting can be applied to several neutrophil-driven pathologies.
- 27 January 2022
- Published by American Society of Hematology in Blood
- Vol. 139 (4) , 597-607
Microlyse: a thrombolytic agent that targets VWF for clearance of microvascular thrombosis
Thrombotic microangiopathies are hallmarked by attacks of disseminated microvascular thrombosis. In thrombotic thrombocytopenic purpura (TTP), this is caused by a rise in thrombogenic ultra-large von Willebrand factor (VWF) multimers because of ADAMTS13 deficiency. We previously reported that systemic plasminogen activation is therapeutic in a TTP mouse model. In contrast to its natural activators (ie, tissue plasminogen activator and urokinase plasminogen activator [uPA]), plasminogen can directly bind to VWF. For optimal efficacy and safety, we aimed to focus and accelerate plasminogen activation at sites of microvascular occlusion. We here describe the development and characterization of Microlyse, a fusion protein consisting of a high-affinity VHH targeting the CT/CK domain of VWF and the protease domain of uPA, for localized plasminogen activation on microthrombi. Microlyse triggers targeted destruction of platelet-VWF complexes by plasmin on activated endothelial cells and in agglutination studies. At equal molar concentrations, Microlyse degrades microthrombi sevenfold more rapidly than blockade of platelet-VWF interactions with a bivalent humanized VHH (caplacizumab*). Finally, Microlyse attenuates thrombocytopenia and tissue damage (reflected by increased plasma lactate dehydrogenase activity, as well as PAI-1 and fibrinogen levels) more efficiently than caplacizumab* in an ADAMTS13−/− mouse model of TTP, without affecting hemostasis in a tail-clip bleeding model. These findings show that targeted thrombolysis of VWF by Microlyse is an effective strategy for the treatment of TTP and might hold value for other forms of VWF-driven thrombotic disease.
- 27 January 2022
- Published by American Society of Hematology in Blood
- Vol. 139 (4) , 597-607
Microlyse: a thrombolytic agent that targets VWF for clearance of microvascular thrombosis
Thrombotic microangiopathies are hallmarked by attacks of disseminated microvascular thrombosis. In thrombotic thrombocytopenic purpura (TTP), this is caused by a rise in thrombogenic ultra-large von Willebrand factor (VWF) multimers because of ADAMTS13 deficiency. We previously reported that systemic plasminogen activation is therapeutic in a TTP mouse model. In contrast to its natural activators (ie, tissue plasminogen activator and urokinase plasminogen activator [uPA]), plasminogen can directly bind to VWF. For optimal efficacy and safety, we aimed to focus and accelerate plasminogen activation at sites of microvascular occlusion. We here describe the development and characterization of Microlyse, a fusion protein consisting of a high-affinity VHH targeting the CT/CK domain of VWF and the protease domain of uPA, for localized plasminogen activation on microthrombi. Microlyse triggers targeted destruction of platelet-VWF complexes by plasmin on activated endothelial cells and in agglutination studies. At equal molar concentrations, Microlyse degrades microthrombi sevenfold more rapidly than blockade of platelet-VWF interactions with a bivalent humanized VHH (caplacizumab*). Finally, Microlyse attenuates thrombocytopenia and tissue damage (reflected by increased plasma lactate dehydrogenase activity, as well as PAI-1 and fibrinogen levels) more efficiently than caplacizumab* in an ADAMTS13−/− mouse model of TTP, without affecting hemostasis in a tail-clip bleeding model. These findings show that targeted thrombolysis of VWF by Microlyse is an effective strategy for the treatment of TTP and might hold value for other forms of VWF-driven thrombotic disease.
- Top Cited PapersOpen Access
S100A8/A9 Is a Marker for the Release of Neutrophil Extracellular Traps and Induces Neutrophil Activation
Neutrophils are the most abundant innate immune cells in the circulation and they are the first cells recruited to sites of infection or inflammation. Almost half of the intracellular protein content in neutrophils consists of S100A8 and S100A9, though there has been controversy about their actual localization. Once released extracellularly, these proteins are thought to act as damage-associated molecular patterns (DAMPs), though their mechanism of action is not well understood. These S100 proteins mainly form heterodimers (S100A8/A9, also known as calprotectin) and this heterocomplex is recognized as a useful biomarker for several inflammatory diseases. We observed that S100A8/A9 is highly present in the cytoplasmic fraction of neutrophils and is not part of the granule content. Furthermore, we found that S100A8/A9 was not released in parallel with granular content but upon the formation of neutrophil extracellular traps (NETs). Accordingly, neutrophils of patients with chronic granulomatous disease, who are deficient in phorbol 12-myristate 13-acetate (PMA)-induced NETosis, did not release S100A8/A9 upon PMA stimulation. Moreover, we purified S100A8/A9 from the cytoplasmic fraction of neutrophils and found that S100A8/A9 could induce neutrophil activation, including adhesion and CD11b upregulation, indicating that this DAMP might amplify neutrophil activation.
Top Cited PapersOpen AccessS100A8/A9 Is a Marker for the Release of Neutrophil Extracellular Traps and Induces Neutrophil Activation
Neutrophils are the most abundant innate immune cells in the circulation and they are the first cells recruited to sites of infection or inflammation. Almost half of the intracellular protein content in neutrophils consists of S100A8 and S100A9, though there has been controversy about their actual localization. Once released extracellularly, these proteins are thought to act as damage-associated molecular patterns (DAMPs), though their mechanism of action is not well understood. These S100 proteins mainly form heterodimers (S100A8/A9, also known as calprotectin) and this heterocomplex is recognized as a useful biomarker for several inflammatory diseases. We observed that S100A8/A9 is highly present in the cytoplasmic fraction of neutrophils and is not part of the granule content. Furthermore, we found that S100A8/A9 was not released in parallel with granular content but upon the formation of neutrophil extracellular traps (NETs). Accordingly, neutrophils of patients with chronic granulomatous disease, who are deficient in phorbol 12-myristate 13-acetate (PMA)-induced NETosis, did not release S100A8/A9 upon PMA stimulation. Moreover, we purified S100A8/A9 from the cytoplasmic fraction of neutrophils and found that S100A8/A9 could induce neutrophil activation, including adhesion and CD11b upregulation, indicating that this DAMP might amplify neutrophil activation.
- 5 November 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (45)
A reactive center loop–based prediction platform to enhance the design of therapeutic SERPINs
Significance: Serine protease inhibitors (SERPINs) regulate vital physiological processes. Considerable research effort has gone into the development of SERPINs as therapeutic agents. One of the development goals is SERPIN modification for improved specificity toward desired target(s). The specificity and potency of SERPINs can be altered by changing their reactive center loop (RCL). Currently, predicting these properties of a RCL sequence is almost impossible. By characterizing 160 α1-antitrypsin RCL variants with single–amino acid substitutions, we developed a SERPIN RCL-based platform that predicts the inhibitory behavior for SERPIN variants with compounded RCL mutations. This platform was applied to design a next-generation SERPIN against activated protein C and provides evidence for its value in the treatment of hemophilia A.
- 5 November 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (45)
A reactive center loop–based prediction platform to enhance the design of therapeutic SERPINs
Significance: Serine protease inhibitors (SERPINs) regulate vital physiological processes. Considerable research effort has gone into the development of SERPINs as therapeutic agents. One of the development goals is SERPIN modification for improved specificity toward desired target(s). The specificity and potency of SERPINs can be altered by changing their reactive center loop (RCL). Currently, predicting these properties of a RCL sequence is almost impossible. By characterizing 160 α1-antitrypsin RCL variants with single–amino acid substitutions, we developed a SERPIN RCL-based platform that predicts the inhibitory behavior for SERPIN variants with compounded RCL mutations. This platform was applied to design a next-generation SERPIN against activated protein C and provides evidence for its value in the treatment of hemophilia A.
- Open Access
- 15 October 2021
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 20 (2) , 353-365
Targeted SERPIN (TaSER): A dual‐action antithrombotic agent that targets platelets for SERPIN delivery
- 15 October 2021
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 20 (2) , 353-365
Open AccessTargeted SERPIN (TaSER): A dual‐action antithrombotic agent that targets platelets for SERPIN delivery